HNC1058

HNC1058 is an investigational small molecule drug that acts as an autotaxin (ATX) inhibitor. It is being developed primarily for the treatment of idiopathic pulmonary fibrosis and systemic sclerosis. The drug targets autotaxin, a secreted enzyme (also known as ectonucleotide pyrophosphatase/phosphodiesterase 2 or ENPP2) that converts lysophosphatidylcholine into lysophosphatidic acid (LPA), a bioactive lipid involved in fibrosis and other pathological processes. By inhibiting ATX, HNC1058 aims to disrupt the ATX-LPA signaling axis implicated in fibrotic diseases. The drug is administered orally as a capsule and has completed Phase 1 clinical trials in healthy volunteers in the United States[1][2][3][5][6].